Cortical and raphe GABA A , AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine
Preprint
Abstract
At sub-anaesthetic doses, ketamine, a non competitive N-methyl-d-aspartate (NMDA) receptor antagonist, has demonstrated remarkable and rapid antidepressant (AD) efficacy in patients with treatment-resistant depression (TRD). However, its mechanism of action of ketamine is not fully understood. Since comorbid depression and anxiety disorders often occur, GABAergic/inhibitory and glutamatergic/excitatory drug treatments may be co-administered in these patients. Information regarding this combination is critical to establish efficacy or treatment restrictions to maximize translation from animal models to TRD patients, effectiveness and safety. To assess the specific role of excitatory/inhibitory neurotransmission in the medial prefrontal cortex-raphe nuclei (mPFC-DRN) circuit in the sustained antidepressant-like activity (AD) of ketamine (at t24h post dose), AMPA-R antagonist (intra-DRN) and GABA A -R agonist (intra-mPFC) were co-administered with ketamine (intra-mPFC). Twenty-four hours later, responses in the forced swim test (FST) and neurochemical consequences on extracellular mPFC glutamate, GABA and 5-HT levels were measured in BALB/cJ mice. Intra-DRN NBQX prevented the sustained AD-like activity of ketamine evidenced by decreases in FST swimming duration and blunted cortical 5-HT ext and Glu ext. Intra-mPFC muscimol blocked ketamine AD-like activity and its effects on cortical 5-HT ext . Moreover, a selective glutamate transporter GLT-1 inhibitor, dihydrokainic acid (DHK) locally perfused into the mPFC produced an AD-like activity at t24h associated with robust increases in mPFC 5-HT ext , Glu ext and GABA ext . Thus, the sustained AD-like activity of ketamine is triggered by AMPA-R activation in the DRN and 5-HT - glutamate release in the mPFC, but limited by GABA A -R activation - GABA release in the mPFC. The local blockade of GLT-1 in the mPFC also mimics the rapid responses of ketamine, thus highlighting the role of neuronal-glial adaptation in these effects. These results also suggests the need to test for the concomitant prescription of ketamine and BZD to see whether its sustained antidepressant activity is maintained in TRD patients.Keywords
All Related Versions
- Published version: Pharmacology Biochemistry and Behavior, 192, 172913.
This publication has 65 references indexed in Scilit:
- Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug InteractionsThe Journal of Clinical Psychiatry, 2017
- The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine UseThe Journal of Clinical Psychiatry, 2017
- Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable StressJournal of Neuroscience, 2016
- Activation of a ventral hippocampus–medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamineMolecular Psychiatry, 2015
- Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacyTherapeutic Advances in Psychopharmacology, 2013
- Strain‐dependent serotonin neuron feedback control: role of serotonin2CreceptorsJournal of Neurochemistry, 2010
- Rapid and precise method to locate microdialysis probe implantation in the rodent brainJournal of Neuroscience Methods, 2004
- Assessing antidepressant activity in rodents: recent developments and future needsTrends in Pharmacological Sciences, 2002
- Antidepressant effects of ketamine in depressed patientsBiological Psychiatry, 2000
- Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal CellsNeuropharmacology, 1997